Synonyms: Agamree® | VBP-15 | VBP15
vamorolone is an approved drug (FDA & EMA (2023))
Compound class:
Synthetic organic
Comment: Vamorolone (VBP15) is a novel, oral non-hormonal steroid modulator, that was investigated in Duchenne muscular dystrophy. It is a multi-functional drug that exhibits anti-inflammatory, membrane stabilisation, and mineralocorticoid receptor antagonist activities. Vamorolone was proposed as a potential replacement for the corticosteroids that are currently used in DMD, as it appears to cause fewer of the common corticosteroid adverse effects [4].
|
|
Bioactivity Comments |
VBP15 is reported to retain NF-κB inhibition (EC50 65.9nM), but without deleterious glucocorticoid side effect profiles [3]. It does not activate other steroid hormone receptors [1]. Neither [3] nor [1] report ligand binding affinity for VBP15 vs. the glucocorticoid receptor. |
Selectivity at nuclear hormone receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|